Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.
Identifieur interne : 000439 ( Main/Exploration ); précédent : 000438; suivant : 000440Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.
Auteurs : Svetlana Shcherbik [États-Unis] ; Nicholas Pearce [États-Unis] ; Irina Kiseleva [Russie] ; Natalie Larionova [Russie] ; Larisa Rudenko [Russie] ; Xiyan Xu [États-Unis] ; David E. Wentworth [États-Unis] ; Tatiana Bousse [États-Unis]Source :
- Journal of virological methods [ 1879-0984 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Données de séquences moléculaires, Embryon de poulet, Russie, Sous-type H2N2 du virus de la grippe A (immunologie), Tests d'inhibition de l'hémagglutination, Vaccins antigrippaux (immunologie), Vaccins antigrippaux (économie), Virologie (), Virus influenza B (immunologie), Virus recombinants.
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , economics : Influenza Vaccines.
- geographic : Russia.
- immunology : Influenza A Virus, H2N2 Subtype, Influenza B virus, Influenza Vaccines.
- methods : Virology.
- Animals, Chick Embryo, Hemagglutination Inhibition Tests, Molecular Sequence Data, Reassortant Viruses.
Abstract
Cold-adapted influenza strains A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69, originally developed in Russia, have been reliable master donors of attenuation for preparing live attenuated influenza vaccines (LAIV). The classical strategy for generating LAIV reassortants is robust, but has some disadvantages. The generation of reassortants requires at least 3 passages under selective conditions after co-infection; each of these selective passages takes six days. Screening the reassortants for a genomic composition traditionally starts after a second limiting dilution cloning procedure, and the number of suitable reassortants is limited. We developed a new approach to shorten process of preparing LAIV seed viruses. Introducing the genotyping of reassortants by pyrosequencing and monitoring sequence integrity of surface antigens starting at the first selective passage allowed specific selection of suitable reassortants for the next cloning procedure and also eliminate one of the group selective passage in vaccine candidate generation. Homogeneity analysis confirmed that reducing the number of selective passages didn't affect the quality of LAIV seed viruses. Finally, the two-way hemagglutination inhibition test, implemented for all the final seed viruses, confirmed that any amino acid substitutions acquired by reassortants during egg propagation didn't affect antigenicity of the vaccine. Our new strategy reduces the time required to generate a vaccine and was used to generate seasonal LAIVs candidates for the 2012/2013, 2014/2015, and 2015/2016 seasons more rapidly.
DOI: 10.1016/j.jviromet.2015.10.009
PubMed: 26519883
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000060
- to stream PubMed, to step Curation: 000060
- to stream PubMed, to step Checkpoint: 000048
- to stream Ncbi, to step Merge: 000C37
- to stream Ncbi, to step Curation: 000C37
- to stream Ncbi, to step Checkpoint: 000C37
- to stream Main, to step Merge: 000439
- to stream Main, to step Curation: 000439
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.</title><author><name sortKey="Shcherbik, Svetlana" sort="Shcherbik, Svetlana" uniqKey="Shcherbik S" first="Svetlana" last="Shcherbik">Svetlana Shcherbik</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States; Battelle, Atlanta, GA 30329, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States; Battelle, Atlanta, GA 30329</wicri:regionArea><wicri:noRegion>GA 30329</wicri:noRegion></affiliation></author><author><name sortKey="Pearce, Nicholas" sort="Pearce, Nicholas" uniqKey="Pearce N" first="Nicholas" last="Pearce">Nicholas Pearce</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States; Battelle, Atlanta, GA 30329, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States; Battelle, Atlanta, GA 30329</wicri:regionArea><wicri:noRegion>GA 30329</wicri:noRegion></affiliation></author><author><name sortKey="Kiseleva, Irina" sort="Kiseleva, Irina" uniqKey="Kiseleva I" first="Irina" last="Kiseleva">Irina Kiseleva</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Institute of Experimental Medicine, Department of Virology, St. Petersburg</wicri:regionArea><wicri:noRegion>St. Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Larionova, Natalie" sort="Larionova, Natalie" uniqKey="Larionova N" first="Natalie" last="Larionova">Natalie Larionova</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Institute of Experimental Medicine, Department of Virology, St. Petersburg</wicri:regionArea><wicri:noRegion>St. Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Institute of Experimental Medicine, Department of Virology, St. Petersburg</wicri:regionArea><wicri:noRegion>St. Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Xiyan" sort="Xu, Xiyan" uniqKey="Xu X" first="Xiyan" last="Xu">Xiyan Xu</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea><wicri:noRegion>GA 30333</wicri:noRegion></affiliation></author><author><name sortKey="Wentworth, David E" sort="Wentworth, David E" uniqKey="Wentworth D" first="David E" last="Wentworth">David E. Wentworth</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea><wicri:noRegion>GA 30333</wicri:noRegion></affiliation></author><author><name sortKey="Bousse, Tatiana" sort="Bousse, Tatiana" uniqKey="Bousse T" first="Tatiana" last="Bousse">Tatiana Bousse</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States. Electronic address: tbousse@cdc.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea><wicri:noRegion>GA 30333</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26519883</idno><idno type="pmid">26519883</idno><idno type="doi">10.1016/j.jviromet.2015.10.009</idno><idno type="wicri:Area/PubMed/Corpus">000060</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000060</idno><idno type="wicri:Area/PubMed/Curation">000060</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000060</idno><idno type="wicri:Area/PubMed/Checkpoint">000048</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000048</idno><idno type="wicri:Area/Ncbi/Merge">000C37</idno><idno type="wicri:Area/Ncbi/Curation">000C37</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C37</idno><idno type="wicri:Area/Main/Merge">000439</idno><idno type="wicri:Area/Main/Curation">000439</idno><idno type="wicri:Area/Main/Exploration">000439</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.</title><author><name sortKey="Shcherbik, Svetlana" sort="Shcherbik, Svetlana" uniqKey="Shcherbik S" first="Svetlana" last="Shcherbik">Svetlana Shcherbik</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States; Battelle, Atlanta, GA 30329, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States; Battelle, Atlanta, GA 30329</wicri:regionArea><wicri:noRegion>GA 30329</wicri:noRegion></affiliation></author><author><name sortKey="Pearce, Nicholas" sort="Pearce, Nicholas" uniqKey="Pearce N" first="Nicholas" last="Pearce">Nicholas Pearce</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States; Battelle, Atlanta, GA 30329, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States; Battelle, Atlanta, GA 30329</wicri:regionArea><wicri:noRegion>GA 30329</wicri:noRegion></affiliation></author><author><name sortKey="Kiseleva, Irina" sort="Kiseleva, Irina" uniqKey="Kiseleva I" first="Irina" last="Kiseleva">Irina Kiseleva</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Institute of Experimental Medicine, Department of Virology, St. Petersburg</wicri:regionArea><wicri:noRegion>St. Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Larionova, Natalie" sort="Larionova, Natalie" uniqKey="Larionova N" first="Natalie" last="Larionova">Natalie Larionova</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Institute of Experimental Medicine, Department of Virology, St. Petersburg</wicri:regionArea><wicri:noRegion>St. Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Experimental Medicine, Department of Virology, St. Petersburg, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Institute of Experimental Medicine, Department of Virology, St. Petersburg</wicri:regionArea><wicri:noRegion>St. Petersburg</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Xiyan" sort="Xu, Xiyan" uniqKey="Xu X" first="Xiyan" last="Xu">Xiyan Xu</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea><wicri:noRegion>GA 30333</wicri:noRegion></affiliation></author><author><name sortKey="Wentworth, David E" sort="Wentworth, David E" uniqKey="Wentworth D" first="David E" last="Wentworth">David E. Wentworth</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea><wicri:noRegion>GA 30333</wicri:noRegion></affiliation></author><author><name sortKey="Bousse, Tatiana" sort="Bousse, Tatiana" uniqKey="Bousse T" first="Tatiana" last="Bousse">Tatiana Bousse</name><affiliation wicri:level="1"><nlm:affiliation>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333, United States. Electronic address: tbousse@cdc.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, MS-G16, 1600 Clifton Road, Atlanta, GA 30333</wicri:regionArea><wicri:noRegion>GA 30333</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of virological methods</title><idno type="eISSN">1879-0984</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chick Embryo</term><term>Hemagglutination Inhibition Tests</term><term>Influenza A Virus, H2N2 Subtype (immunology)</term><term>Influenza B virus (immunology)</term><term>Influenza Vaccines (economics)</term><term>Influenza Vaccines (immunology)</term><term>Molecular Sequence Data</term><term>Reassortant Viruses</term><term>Russia</term><term>Virology (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Données de séquences moléculaires</term><term>Embryon de poulet</term><term>Russie</term><term>Sous-type H2N2 du virus de la grippe A (immunologie)</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (économie)</term><term>Virologie ()</term><term>Virus influenza B (immunologie)</term><term>Virus recombinants</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Russia</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza B virus</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Virology</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chick Embryo</term><term>Hemagglutination Inhibition Tests</term><term>Molecular Sequence Data</term><term>Reassortant Viruses</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Données de séquences moléculaires</term><term>Embryon de poulet</term><term>Russie</term><term>Tests d'inhibition de l'hémagglutination</term><term>Virologie</term><term>Virus recombinants</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cold-adapted influenza strains A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69, originally developed in Russia, have been reliable master donors of attenuation for preparing live attenuated influenza vaccines (LAIV). The classical strategy for generating LAIV reassortants is robust, but has some disadvantages. The generation of reassortants requires at least 3 passages under selective conditions after co-infection; each of these selective passages takes six days. Screening the reassortants for a genomic composition traditionally starts after a second limiting dilution cloning procedure, and the number of suitable reassortants is limited. We developed a new approach to shorten process of preparing LAIV seed viruses. Introducing the genotyping of reassortants by pyrosequencing and monitoring sequence integrity of surface antigens starting at the first selective passage allowed specific selection of suitable reassortants for the next cloning procedure and also eliminate one of the group selective passage in vaccine candidate generation. Homogeneity analysis confirmed that reducing the number of selective passages didn't affect the quality of LAIV seed viruses. Finally, the two-way hemagglutination inhibition test, implemented for all the final seed viruses, confirmed that any amino acid substitutions acquired by reassortants during egg propagation didn't affect antigenicity of the vaccine. Our new strategy reduces the time required to generate a vaccine and was used to generate seasonal LAIVs candidates for the 2012/2013, 2014/2015, and 2015/2016 seasons more rapidly. </div></front></TEI><affiliations><list><country><li>Russie</li><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Shcherbik, Svetlana" sort="Shcherbik, Svetlana" uniqKey="Shcherbik S" first="Svetlana" last="Shcherbik">Svetlana Shcherbik</name></noRegion><name sortKey="Bousse, Tatiana" sort="Bousse, Tatiana" uniqKey="Bousse T" first="Tatiana" last="Bousse">Tatiana Bousse</name><name sortKey="Pearce, Nicholas" sort="Pearce, Nicholas" uniqKey="Pearce N" first="Nicholas" last="Pearce">Nicholas Pearce</name><name sortKey="Wentworth, David E" sort="Wentworth, David E" uniqKey="Wentworth D" first="David E" last="Wentworth">David E. Wentworth</name><name sortKey="Xu, Xiyan" sort="Xu, Xiyan" uniqKey="Xu X" first="Xiyan" last="Xu">Xiyan Xu</name></country><country name="Russie"><noRegion><name sortKey="Kiseleva, Irina" sort="Kiseleva, Irina" uniqKey="Kiseleva I" first="Irina" last="Kiseleva">Irina Kiseleva</name></noRegion><name sortKey="Larionova, Natalie" sort="Larionova, Natalie" uniqKey="Larionova N" first="Natalie" last="Larionova">Natalie Larionova</name><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000439 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000439 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26519883
|texte= Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26519883" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |